Jan Beumer
Professor (PAR)
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Summary of treatment de-escalation. Overview of dose de-escalation, number ( n ) of patients at each level, and number of patients experiencing a DLT at each dose level. bid, twice daily; D, day; IV, intravenously; PO, orally; qd, once a day.
Year:
2025
Elimusertib concentrations by toxicity. DLT occurrence and week 1 cumulative elimusertib based on day 2 AUC 0–12 hours by cisplatin dose. Open circles, individual patients; solid dash, geometric mean.
Year:
2025
Purpose: The ataxia telangiectasia and Rad3–related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin. Patients and Methods: Patients with advanced solid tumors who had received 2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m 2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy. Results: Fifteen patients were enrolled. Dose level −2 (elimusertib 20 mg once on day 2 and cisplatin 30 mg/m 2 on days 1 and 8) was deemed the maximum tolerated dose; dose-limiting toxicities (DLT) including creatinine increase, hypokalemia, febrile neutropenia, neutropenia, syncope, and thrombocytopenia, required dose de-escalation. Although the four patients with the highest elimusertib exposure all experienced hematologic DLTs within 1 week, they also received a higher day 1 cisplatin dose, precluding a definitive association of elimusertib exposure with DLT occurrence. Of 10 evaluable patients, one (10%) with clear-cell ovarian cancer had a partial response, whereas five (50%) had stable disease. Conclusions: Cisplatin combined with elimusertib was associated with hematologic toxicity requiring significant dose de-escalation. Elimusertib pharmacokinetics was consistent with prior studies. Only modest activity was observed. Further clinical evaluation of elimusertib plus cisplatin is not warranted. Significance: Preclinical data suggest synergy between cisplatin and the ataxia telangiectasia and Rad3–related inhibitor elimusertib, leading to this phase Ib trial in advanced solid tumors evaluating feasibility. The results do not support further examination of the combination due to DLTs observed in the absence of robust efficacy.
Year:
2025
Polyadenosine diphosphate–ribose polymerase 1 (PARP‐1) and 2 (PARP‐2) are key DNA repair enzymes that promote single‐strand break repair via the base excision pathway. Niraparib, a PARP inhibitor, has shown clinical efficacy with the reduction of disease progression or death and progression‐free survival benefit across multiple clinical trials, leading to the Food and Drug Administration (FDA) approval for the treatment of advanced and recurrent ovarian cancers. This study presents a robust and simple 5‐min assay designed for the quantitation of the single agent niraparib in human plasma utilizing liquid chromatography–tandem mass spectrometry (LC‐MS/MS). A 50 μL volume of plasma was subjected to protein precipitation, followed by chromatographic separation using a Phenomenex Kinetex C18 column (2.6 μm, 50 × 2.1 mm) and a gradient mobile phase system consisting of 0.1% formic acid in both water and acetonitrile during a 5‐min run time. Mass spectrometric detection was achieved using a SCIEX 6500 + tandem mass spectrometer with electrospray positive‐mode ionization. With a stable isotopic internal standard, our assay met the criteria outlined by the FDA guidance for bioanalytical method validation, demonstrating robust performance within the range from 5 to 5000 ng/mL. This assay will support future clinical studies by defining niraparib pharmacokinetics.
Year:
2025
Ataxia‐telangiectasia and Rad3‐related (ATR) protein kinase is an essential regulator of the DNA damage response (DDR) at stalled and collapsed replication forks. Tuvusertib (M1774) is a selective, orally available small molecule ATR inhibitor currently in preclinical and clinical development for cancer treatment. This study presents a robust and simple 5‐min assay designed for the quantification of single agent tuvusertib in human plasma utilizing liquid chromatography tandem mass spectrometry (LC‐MS/MS). A 20 μL volume of plasma was subjected to protein precipitation, followed by chromatographic separation using a Phenomenex Synergi Polar‐RP (4 μm, 2.1 × 50 mm) and a gradient mobile phase system consisting of 0.1% formic acid in both water and acetonitrile during a 4‐min run time. Mass spectrometric detection was achieved using a SCIEX 6500+ tandem mass spectrometer with electrospray positive‐mode ionization. With a stable isotopic internal standard, our assay met the criteria outlined by the Food and Drug Administration guidance for bioanalytical method validation, demonstrating robust performance within the range from 5 to 5000 ng/mL. This assay will support ongoing and future clinical studies by defining tuvusertib pharmacokinetics.
Year:
2025
The DNA‐dependent protein kinase (DNA‐PK) is an abundant nuclear protein that mediates DNA double‐strand break repair by nonhomologous end joining (NHEJ). As such, DNA‐PK is critical for V(D)J recombination in lymphocytes and for survival in cells exposed to ionizing radiation and clastogens. Peposertib (M3814) is a small molecule DNA‐PK inhibitor currently in preclinical and clinical development for cancer treatment. We have developed a high‐performance liquid chromatography‐mass spectrometry method for quantitating peposertib and its metabolite in 0.1 mL human plasma. After MTBE liquid–liquid extraction, chromatographic separation was achieved with a Phenomenex Synergi polar reverse phase (4 μm, 2 × 50 mm) column and a gradient of 0.1% formic acid in acetonitrile and water over an 8 min run time. Mass spectrometric detection was performed on an ABI SCIEX 4000 with electrospray, positive‐mode ionization. The assay was linear from 10 to 3000 ng/mL for peposertib and 1–300 ng/mL for the metabolite and proved to be both accurate (97.3%–103.7%) and precise (<8.9%CV) fulfilling criteria from the Food and Drug Administration (FDA) guidance on bioanalytical method validation. This liquid chromatography‐tandem mass spectroscopy (LC–MS/MS) assay will support several ongoing clinical studies by defining peposertib pharmacokinetics.
Year:
2024
To support a phase 1 trial in patients with lymphomas, we developed a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for tazemetostat quantitation in 20 μL of human plasma. After protein precipitation, chromatographic separation employed a Kinetex C18 column and a gradient of 0.1% formic acid in both water and acetonitrile, during a 3‐min run time. Detection was achieved using a SCIEX 6500+ tandem mass spectrometer with electrospray positive‐mode ionization. Validation was based on the latest Food and Drug Administration guidance. With a stable isotopic internal standard, the assay was linear within the range of 10–5000 ng/mL and proved to be accurate (91.9%–103.7%) and precise (<4.4% imprecision). Recovery varied between 93.3% and 121.1%, and matrix effect ranged from −25.5% to −4.9%. Hemolysis, lipemia, and dilution did not impact quantitation. Plasma stability was confirmed after three freeze–thaw cycles, 24 h at room temperature, and 4 months at −80°C. Incurred sample reanalysis yielded 94.4% samples within 20% difference ( n = 36). External validation showed a mean bias of −11.1%. Pharmacokinetic (PK) data obtained from three patients suggested variable concentration time profiles, warranting collection of further data. The assay proved to be suitable for tazemetostat quantitation in human plasma and will support clinical studies by defining tazemetostat PKs.
Year:
2024
Collaborators (8)
Paul Frankel
Research Professor
Beckman Research Institute, City of Hope
Arjun Mittra
Assistant Professor
The Ohio State University Comprehensive Cancer Center
Ming Yin
Assistant Professor
The Ohio State University Wexner Medical Center
Yuanquan Yang
The Ohio State University Comprehensive Cancer Center
Anne Noonan
Professor
The Ohio State University Comprehensive Cancer Center
Philippe L. Bedard
University Health Network
Nataliya Uboha
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Mamta Parikh
Associate Professor
University of California Davis Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.